Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE008538 |
ID: | TCMBANKHE008538 |
功能与主治: | Scab and lichen, eczema, neurodermatitis . |
药用植物名: | 土荆皮 |
治疗类型: | 解毒杀虫燥湿止痒药 |
TCM_ID_id: | 4129 |
SymMap_id: | 406 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000440 | deacetylpseudolaricacid c2 | C20H24O7 | 376.4 g/mol | CC(=CC=CC1(C2CCC3(C2(CCC(=CC3)C(=O)O)O)C(=O)O1)C)C(=O)O | |
| TCMBANKIN001361 | pseudolaroside C | 314.32 | |||
| TCMBANKIN003631 | pseudolaricacid e | C20H28O4 | |||
| TCMBANKIN004668 | terchebin | C41H30O27 | 954.66 | C1=C(C=C(C(=C1O)O)O)C(=O)OCC2C3C(C(C(O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5C7C(=CC(=O)C(C7(O6)O)(O)O)C(=O)O3)O)O)OC(=O)C8=CC(=C(C(=C8)O)O)O | |
| TCMBANKIN004890 | Isobutyryl shikonin | 52438-12-7; [(1S)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 2-methylpropanoate; ZINC1702730; (1R)-1-(5,8-DIHYDROXY-1,4-DIOXONAPHTHALEN-2-YL)-4-METHYLPENT-3-EN-1-YL 2-METHYLPROPANOATE; CTK5J8655; MFCD00144512; (1r)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl 2-methylpropanoate; SCHEMBL3298557; C17414; C-56533; 2-methylpropionic acid [(1S)-1-(5,8-dihydroxy-1,4-diketo-2-naphthyl)-4-methyl-pent-3-enyl] ester; Isobutylshikonin; CHEBI:81070; AC1LA0S8; Isobutyrylshikonin; FT-0770577; [(1S)-1-(5,8-dihydroxy-1,4-dioxo-naphthalen-2-yl)-4-methyl-pent-3-enyl] 2-methylpropanoate; isobutyryl shikonin; [(1R)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 2-methylpropanoate; [(1S)-1-(5,8-dihydroxy-1,4-dioxo-2-naphthyl)-4-methyl-pent-3-enyl] 2-methylpropanoate; 2-methylpropanoic acid [(1S)-1-(5,8-dihydroxy-1,4-dioxo-2-naphthyl)-4-methylpent-3-enyl] ester; isobutyrylshikonin | C20H22O6 | 358.4 g/mol | CC(C)C(=O)OC(CC=C(C)C)C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O |
| TCMBANKIN007130 | Coleoside B_qt | 314.37 | |||
| TCMBANKIN007619 | intermedine | AC1NSWV1; (7-hydroxy-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl) 2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoate | C15H25NO5 | 299.36 g/mol | CC(C)C(C(C)O)(C(=O)OCC1=CCN2C1C(CC2)O)O |
| TCMBANKIN010452 | pseudolaricacid d | C20H30O3 | 318.4 g/mol | CC1(CCCC2(C1CCC34C2CCC(C3)C(=C4)C(=O)O)C)CO | |
| TCMBANKIN010749 | alkannin angelate | C21H22O6 | CC=C(C)C(=O)OC(CC=C(C)C)C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O | ||
| TCMBANKIN014357 | pseudolaricacid b-o-β-d-glucopyranoside | C29H38O13 | CC(=CC=CC1(C2CCC3(C2(CCC(=CC3)C(=O)OC)OC(=O)C)C(=O)O1)C)C(=O)OC4C(C(C(C(O4)CO)O)O)O | ||
| TCMBANKIN014578 | pseudolaricacid h | C22H26O6 | 386.4 g/mol | CC1=CCC2(C3CCC2(C=C1)C(=O)OC3(C)C=CC=C(C)C(=O)O)OC(=O)C | |
| TCMBANKIN014713 | methyl (3S,4S,5R)-3,4,5-trihydroxycyclohexene-1-carboxylate | (3S,4S,5R)-3,4,5-trihydroxycyclohexene-1-carboxylic acid methyl ester; (3S,4S,5R)-3,4,5-trihydroxy-1-cyclohexenecarboxylic acid methyl ester | C8H12O5 | 188.18 | COC(=O)C1=CC(C(C(C1)O)O)O |
| TCMBANKIN015120 | 3-(1,1-dimethyl allyl) herniarin | 7-Methoxy-3-(2-methylbut-3-en-2-yl)-1-benzopyran-2-one; 3-(1,1-Dimethyl allyl) herniarin; 3-(1,1-Dimethyl-2-propenyl)-7-methoxy-2H-1-benzopyran-2-one; AC1L4BBZ; 3-(1,1-Dimethylallyl)-7-methoxycoumarin; 7-methoxy-3-(2-methylbut-3-en-2-yl)chromen-2-one; 7-methoxy-3-(2-methylbut-3-en-2-yl)-2H-chromen-2-one; CTK1A5922; 3-(1,1-Dimethylallyl)herniarin; 3-(1,1-dimethyl allyl)herniarin; DTXSID70175138; 20958-63-8 | C15H16O3 | 244.28 g/mol | CC(C)(C=C)C1=CC2=C(C=C(C=C2)OC)OC1=O |
| TCMBANKIN015371 | pseudolarifuroic | C30H42O4 | 466.65 | ||
| TCMBANKIN017576 | Alkannan | 5,8-dihydroxy-2-isohexylnaphthalene-1,4-dione; ZINC13335177; alkannan; 517-90-8; DTXSID90199654; FZS19WML2L; UNII-FZS19WML2L; 5,8-dihydroxy-2-isohexyl-1,4-naphthoquinone; SCHEMBL12810826; ACM517908; 5,8-dihydroxy-2-isohexyl-naphthalene-1,4-dione; AC1NSVEV; 5,8-dihydroxy-2-(4-methylpentyl)naphthalene-1,4-dione | C16H18O4 | 274.31 | CC(C)CCCC1=CC(=O)C2=C(C=CC(=C2C1=O)O)O |
| TCMBANKIN019228 | lithospermidin A | [(E)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-hydroxy-4-methylpent-2-enyl] 2-methylbutanoate; AC1NSXLW; lithospermidin a | C21H24O7 | 388.41 | CCC(C)C(=O)OC(C=CC(C)(C)O)C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O |
| TCMBANKIN021112 | SKM | 3,4,5-Trihydroxy-1-cyclohexenecarboxylic acid; C00493; HSDB 3537; CHEBI:16119; (3R,4S,5R)-(−)-3,4,5-Trihydroxy-1-cyclohexenecarboxylic acid; S5375_SIGMA; SMP1_000326; KBio2_001712; 1-Cyclohexene-1-carboxylic acid, 3,4,5-trihydroxy-, (3R-(3alpha,4alpha,5beta)); KBio1_001528; (3R,4S,5R)-(-)-3,4,5-Trihydroxy-1-cyclohexenecarboxylic acid; SPBio_001555; SDCCGMLS-0066740.P001; 1-Cyclohexene-1-carboxylic acid, 3,4,5-trihydroxy-, (3R-(3alpha,4alpha,5beta))-; NSC 59257; SPECTRUM1502256; EINECS 205-334-2; KBio2_006848; Shikimic acid [3R-(3alpha,4alpha,5beta)]-3,4,5-Trihydroxy-1-cyclohexene-1-carboxylic acid; L-Shikimic acid; InChI=1/C7H10O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1,4-6,8-10H,2H2,(H,11,12)/t4-,5-,6-/m1/s; NCGC00142601-01; KBioSS_001712; 1-Cyclohexene-1-carboxylic acid, 3,4,5-trihydroxy-, (3R,4S,5R)- (9CI); SBB012371; (3R,4S,5R)-3,4,5-trihydroxy-1-cyclohexenecarboxylic acid; Spectrum3_001541; (3R,4S,5R)-3,4,5-trihydroxycyclohexene-1-carboxylic acid; 1-Cyclohexene-1-carboxylic acid, 3,4,5-trihydroxy-, (3R-(3alpha,4alpha,5beta))- (9CI); KBio2_004280; Spectrum2_001508; (3R,4S,5R)-3,4,5-Trihydroxycyclohex-1-enecarboxylic acid; (-)-Shikimic acid; BSPBio_002982; CCRIS 7681; 1-cyclohexene-1-carboxylic acid, 3,4,5-trihydroxy-, (3R,4S,5R)-; KBio3_002482; MEGxp0_001939; Spectrum5_000386; SpecPlus_000488; DHK; Spectrum4_001853; DivK1c_006584; [3R-(3alpha,4alpha,5beta)]-3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid; Spectrum_001232; 3alpha,4alpha,5beta-Trihydroxy-1-cyclohexene-1-carboxylic acid; SR-01000632403-1; KBioGR_002287; (-)-3,4,5-Trihydroxy-1-cyclohexene-1-carboxylic acid; S-5181; (3R,4S,5R)-3,4,5-TRIHYDROXYCYCLOHEX-1-ENE-1-CARBOXYLIC ACID | C7H10O5 | 174.15 | CC(C)(C)OC(=O)N1C2=C(C=N1)C(=CC=C2)Br |
| TCMBANKIN021286 | isobyakangelicol | C16914; Anhydrobyakangelicin; AC1NSWYH; 4-methoxy-9-(3-methyl-2-oxobutoxy)furo[3,2-g]chromen-7-one; Isobyakangelicol; CHEBI:80792 | C17H16O6 | 316.3 g/mol | CC(C)C(=O)COC1=C2C(=C(C3=C1OC(=O)C=C3)OC)C=CO2 |
| TCMBANKIN022751 | Lithospermidin B | [(E)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-hydroxy-4-methylpent-2-enyl] 3-methylbutanoate; AC1NSXLZ; 83415-79-6; lithospermidin b | C21H24O7 | 388.4 g/mol | CC(C)CC(=O)OC(C=CC(C)(C)O)C1=CC(=C2C(=O)C=CC(=O)C2=C1O)O |
| TCMBANKIN022995 | pseudolaricacid f | C22H26O7 | 402.4 g/mol | CC1=CCC2(C3CCC2(CC1=O)C(=O)OC3(C)C=CC=C(C)C(=O)O)OC(=O)C | |
| TCMBANKIN023038 | pseudolaricacid a-o-β-d-glucopyranoside | C28H38O11 | |||
| TCMBANKIN026070 | Shinjulactone K | 94451-22-6; Picrasane-1,16-dione, 12-(actyloxy)-2,12-dihydroxy-, (2.alpha.,11.alpha.,12.alpha.); AIDS-026415; Picrasane-1,16-dione, 12-(actyloxy)-2,12-dihydroxy-, (2alpha,11alpha,12alpha); shinjulactone k; AIDS026415 | C22H32O7 | 408.49 | CC1CC(C(=O)C2(C1CC3C4(C2C(C(C(C4CC(=O)O3)C)OC(=O)C)O)C)C)O |
| TCMBANKIN026181 | (2R,3R,4S,5R,6S)-3-isopropyl-2-methylol-6-(phenoxy)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-tetrahydropyran-3,4,5-triol | (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-3-isopropyl-6-(phenoxy)-5-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]tetrahydropyran-3,4,5-triol; (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-(phenoxy)-3-propan-2-yl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol; 134515-66-5; (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-3-isopropyl-6-(phenoxy)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-tetrahydropyran-3,4,5-triol; (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-(phenoxy)-3-propan-2-yl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-oxane-3,4,5-triol | C21H32O12 | 476.47 | CC(C)C1(C(OC(C(C1O)(O)OC2C(C(C(C(O2)CO)O)O)O)OC3=CC=CC=C3)CO)O |
| TCMBANKIN026482 | Docosyl caffeate | docosyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; ST24046665; DOCOSYL (2E)-3-(3,4-DIHYDROXYPHENYL)PROP-2-ENOATE; MolPort-023-298-972; ZINC73220104; AKOS022184902; 2-Propenoic acid,3-(3,4-dihydroxyphenyl)-, docosyl ester, (2E)-; 3,4-Dihydroxycinnamic acid docosyl ester; Docosyl caffeate, analytical standard; W2091; docosyl caffeate; 28593-92-2; 3,4-Dihydroxybenzeneacrylic acid docosyl ester; CHEMBL1933863; SCHEMBL883452; 9375AF; AK104300; Docosyl 3-(3,4-dihydroxyphenyl)acrylate; Caffeic acid docosyl ester; 50432-89-8; AC1NSUY6 | C31H52O4 | 488.74 | CCCCCCCCCCCCCCCCCCCCCCOC(=O)C=CC1=CC(=C(C=C1)O)O |
| TCMBANKIN028179 | pseudolaricacid c2 | C22H26O8 | 418.4 g/mol | CC(=CC=CC1(C2CCC3(C2(CCC(=CC3)C(=O)O)OC(=O)C)C(=O)O1)C)C(=O)O | |
| TCMBANKIN031411 | pseudolaricacid g | C22H28O7 | 404.5 g/mol | CC1=CCC2(C3CCC2(CC1O)C(=O)OC3(C)C=CC=C(C)C(=O)O)OC(=O)C | |
| TCMBANKIN033157 | pseudolarifuroicacid | C30H42O4 | 466.7 g/mol | CC(CC1=CC(=CO1)C(=O)O)C2CCC3(C2(CCC4C3=CCC5C4(CCC(=O)C5(C)C)C)C)C | |
| TCMBANKIN033621 | deacetylpseudolaricacid a | C20H26O5 | 346.4 g/mol | CC1=CCC23CCC(C2(CC1)O)C(OC3=O)(C)C=CC=C(C)C(=O)O | |
| TCMBANKIN034697 | tert-o-methyl byakangelicin | tert-o-methylbyakangelicin; AC1NSY8Y; 9-(2-hydroxy-3-methoxy-3-methylbutoxy)-4-methoxyfuro[3,2-g]chromen-7-one; 4-Methoxy-9-(2-hydroxy-3-methoxy-3-methylbutoxy)-7H-furo[3,2-g][1]benzopyran-7-one; HMS3327O17 | C18H20O7 | 348.3 g/mol | CC(C)(C(COC1=C2C(=C(C3=C1OC(=O)C=C3)OC)C=CO2)O)OC |
| TCMBANKIN036297 | 6-Hydroxykynurenate | 2-Quinolinecarboxylic acid, 4,6-dihydroxy-; 3778-29-8; C05663; 6-hydroxy-4-oxo-1H-quinoline-2-carboxylic acid; C08480; 6-Hydroxykynurenic acid; 6-hydroxy-4-keto-1H-quinoline-2-carboxylic acid; Quinaldic acid, 4,6-dihydroxy- | C10H7NO4 | 205.17 | C1=CC2=C(C=C1O)C(=O)C=C(N2)C(=O)O |
| TCMBANKIN036839 | Pseudolaric acid B | pseudolaricacid b | 432.5 g/mol | ||
| TCMBANKIN037131 | ononin | 4H-1-Benzopyran-4-one, 7-(beta-D-glucopyranosyloxy)-3-(4-methoxyphenyl)-; MEGxp0_000395; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; LMPK12050014; 486-62-4; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-chromone; Formononetin glucoside; STOCK1N-14986; 75375_FLUKA; 3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranoside; ACon1_000463; ZINC01081322; 3-(4-methoxyphenyl)-7-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]-4-chromenone; CHEBI:7775; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-chromen-4-one; Ononin; C10509; Formononetin 7-O-glucoside; Formononetin-7-O-beta-D-glucopyranoside; Formononetin-7-glucoside | C22H22O9 | 430.405 | [C@@]1([H])(O[H])[C@]([H])(C([H])([H])O[H])O[C@]([H])(Oc2c([H])c([H])c(C(=O)C(c3c([H])c([H])c(OC([H])([H])[H])c([H])c3[H])=C([H])O4)c4c2[H])[C@@]([H])(O[H])[C@]1([H])O[H] |
| TCMBANKIN037146 | NP02140176-38-K | ||||
| TCMBANKIN037201 | Shikonofuran A | [1-[5-(2,5-dihydroxyphenyl)furan-3-yl]-4-methylpent-3-enyl] acetate; AC1NT0DL; 85022-66-8; MolPort-039-339-080; Shikonofuran A | 316.3 g/mol | ||
| TCMBANKIN037305 | pseudolarolide c | C31H48O6 | 516.7 g/mol | CC1CC2(CC(C(=O)O2)C)OC3C1C4(CCC56CC5(C(CCC6C4(C3)C)C(C)(C)O)CCC(=O)OC)C | |
| TCMBANKIN038032 | formononetin | Oprea1_815287; AIDS027672; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one; Isoflavone, 7-hydroxy-4'-methoxy- (8CI); NCI60_042081; NCGC00095207-03; Oprea1_139748; NCIOpen2_005983; SDCCGMLS-0066428.P001; CHEBI:18088; TNP00176; 485-72-3; Formononetol; Isoflavone, 7-hydroxy-4'-methoxy-; 7-hydroxy-3-(4-methoxyphenyl)chromone; Spectrum2_000560; Formononetin; NSC 93360; EINECS 207-623-9; 47752_FLUKA; KBio2_000853; 7-Hydroxy-3-(4-methoxyphenyl)-4-benzopyrone; Spectrum5_000258; KBio3_001519; NSC93360; KBioSS_000853; Spectrum_000373; SPECTRUM102007; KBio2_005989; Biochanin B; KBioGR_001878; NCGC00017269-01; 7-Hydroxy-3-(4′-methoxyphenyl)-4H-benzopyran-4-one; formononetin ; 7-hydroxy-4'-methoxy-isoflavone; BSPBio_002299; ZINC00113304; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)- (9CI); SBB016445; Spectrum3_000660; 7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Spectrum4_001429; DivK1c_006319; KBio2_003421; SPBio_000639; NCGC00095207-01; KBio1_001263; AIDS-027672; 7-Hydroxy-4'-methoxyisoflavone; C00858; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-; NCGC00095207-02; SpecPlus_000223 | C16H12O4 | 268.264 | C1([H])=C(c2c([H])c([H])c(OC([H])([H])[H])c([H])c2[H])C(c3c(O1)c([H])c(O[H])c([H])c3[H])=O |
| TCMBANKIN038453 | β,β-dimethylacrylshikonin | Dmask; CHEBI:81071; beta,beta-Dimethylacrylshikonin; ZINC2014578; (1R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydro-2-naphthalenyl)-4-methyl-3-pentenyl 3-methyl-2-butenoate, AldrichCPR; MFCD00143687; beta,beta-dimethylacrylshikonin; 24502-79-2; [(1R)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 3-methylbut-2-enoate; Dimethylacrylshikonin; b,b-Dimethylacrylshikonin; Ambap24502-79-2; AK115142; Isoarnebin I; CCG-208399; AC1LA0S5; ZINC102967580; SCHEMBL2876200; (1R)-1-(5,8-DIHYDROXY-1,4-DIOXONAPHTHALEN-2-YL)-4-METHYLPENT-3-EN-1-YL 3-METHYLBUT-2-ENOATE; KS-000012LI; [1-(5,8-dihydroxy-1,4-dioxo-2-naphthyl)-4-methyl-pent-3-enyl] 3-methylbut-2-enoate; 2-Butenoic acid, 3-methyl-, (1R)-1-(1,4-dihydro-5,8-dihydroxy-1,4-dioxo-2-naphthalenyl)-4-methyl-3-pentenyl ester; FT-0774263; CJ-31230; [1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 3-methylbut-2-enoate; MolPort-027-835-870; (beta,beta-Dimethylacryl)shikonin; C17415; AKOS016010086; Shikonin beta,beta-dimethylacrylate; ST24046001; CJ-31231; AJ-32569; 2-Butenoic acid, 3-methyl-, 1-(1,4-dihydro-5,8-dihydroxy-1,4-dioxo-2-naphthalenyl)-4-methyl-3-pentenyl ester, (R)- | C21H22O6 | 370.4 g/mol | CC(=CCC(C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)OC(=O)C=C(C)C)C |
| TCMBANKIN038730 | Arnebifuranone | AC1O6QVB; Isoarnebifuranone; 5-[(E)-5-(furan-3-yl)-2-methylpent-2-enyl]-2,3-dimethoxycyclohexa-2,5-diene-1,4-dione | 316.3 g/mol | ||
| TCMBANKIN039015 | Rhizonone | 254.28 g/mol | |||
| TCMBANKIN039088 | Acetylalkannin | ZINC16954710; CHEMBL112415; SCHEMBL4289438; 11-O-Acetylalkannin; Acetylalkannin | 330.3 g/mol | ||
| TCMBANKIN039172 | Tetracosyl caffeate | 516.8 g/mol | |||
| TCMBANKIN039750 | α-Acetoxyisovalerylalkannin | ||||
| TCMBANKIN040652 | O9-Angeloylretronecine | AC1NSXBX; [(7R)-7-hydroxy-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl (E)-2-methylbut-2-enoate | |||
| TCMBANKIN041265 | β,β-Dimethylacrylalkannin | beta,beta-dimethylacrylalkannin | 370.4 g/mol | ||
| TCMBANKIN041744 | pseudolarolide i | C30H44O8 | CC1CC2(CC(C(=O)O2)C)OC3C1C4(CCC56CC7(C(CCC5C4(C3)C)C(OC(=O)CC7OO6)(C)C)O)C | ||
| TCMBANKIN041753 | Pseudolarolide B | 466.7 g/mol | |||
| TCMBANKIN041766 | Shikonofuran C | Shikonofuran C; 85022-64-6; shikonofuran c; AC1NT0DR; BDBM50363752; [1-[5-(2,5-dihydroxyphenyl)furan-3-yl]-4-methylpent-3-enyl] 3-methylbutanoate; CHEMBL1946217 | 358.43 | ||
| TCMBANKIN042000 | 1-methyl-acetylshikonin | CC(=CCC(C1=CC(=C2C(=O)C=CC(=O)C2=C1OC)O)OC(=O)C)C | |||
| TCMBANKIN042113 | Pseudolaric acid C | pseudolaricacid c | 389.4 g/mol | ||
| TCMBANKIN042582 | np02140176-42-k | ||||
| TCMBANKIN042693 | Pseudolarolide A | pseudolarolide a | 468.7 g/mol | ||
| TCMBANKIN042696 | NP02140176-39-Na | ||||
| TCMBANKIN043330 | β-Hydroxyisovalerylshikonin | beta-hydroxyisovalerylshikonin; beta-hydro-xyisovalerylshikonin | 388.4 g/mol | ||
| TCMBANKIN043761 | myoscorpine | C20H31NO6 | 381.5 g/mol | CC=C(C)C(=O)OC1CCN2C1C(=CC2)COC(=O)C(C(C)C)(C(C)O)O | |
| TCMBANKIN044675 | Methyl pseudolarate A | 402.5 g/mol | |||
| TCMBANKIN044980 | isovalerylshikonin | [(1S)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 3-methylbutanoate; CHEMBL463439; isovalerylalkannin; Isovaleryl alkannin; AC1NSX6R; CJ-25124; I14-62674; ZINC1580028 | C21H24O6 | 372.4 g/mol | CC(C)CC(=O)OC(CC=C(C)C)C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O |
| TCMBANKIN045339 | deoxy-delta3,5-tigogenin | ||||
| TCMBANKIN045868 | 2',3'-Dihydroxy-1'-propoxypseudolarate B | ||||
| TCMBANKIN045883 | Eicosyl caffeate | ||||
| TCMBANKIN045920 | Des-O-methyllasiodiplodin | 13,15-dihydroxy-10-oxabicyclo[10.4.0]hexadeca-1(16),12,14-trien-11-one; CHEMBL1669771; des-o-methyllasiodiplodin; AC1NSUF7 | 264.32 g/mol | ||
| TCMBANKIN046117 | Pseudolarolide D | 484.7 g/mol | |||
| TCMBANKIN046253 | NP02140176-41-KNa | ||||
| TCMBANKIN046421 | Acetylshikonin | ZINC16954710; CHEMBL112415; SCHEMBL4289438; 11-O-Acetylalkannin; Acetylalkannin; acetylalkannin | C18H18O6 | 330.332 | c1([H])c(O[H])c(C(=O)C([H])=C([C@]([H])(OC(=O)C([H])([H])[H])C([H])([H])\C([H])=C(/C([H])([H])[H])\C([H])([H])[H])C2=O)c2c(O[H])c1[H] |
| TCMBANKIN046591 | pseudolarolide h | C30H42O7 | |||
| TCMBANKIN046985 | 3,4-trans-(erythro)-3,5-Bis(tripolyphosphate)-4-pentanolide | ||||
| TCMBANKIN047072 | pseudolarolide e | C30H42O6 | |||
| TCMBANKIN047595 | α-methyl-n-butyrylshikonin | CCC(C)C(=O)OC(CC=C(C)C)C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O | |||
| TCMBANKIN047699 | 6''-o-acetylsaikosaponin b3 | C44H72O15 | |||
| TCMBANKIN047742 | hydroxymyoscorpine | C20H31NO7 | 397.5 g/mol | CC=C(C)C(=O)OC1CCN2C1C(=CC2)COC(=O)C(C(C)O)(C(C)(C)O)O | |
| TCMBANKIN048127 | lobelanidine | CHEMBL1473116; CAS-6112-86-3; (1S)-2-[(2R,6R)-6-[(2R)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanol; ZINC13704163; AC1O7GDN; NCGC00016670-01 | C22H29NO2 | 339.471 | C([H])([H])([H])N1[C@@]([H])(C([H])([H])[C@@]([H])(O[H])c2c([H])c([H])c([H])c([H])c2[H])C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C([H])([H])[C@]([H])(O[H])c3c([H])c([H])c([H])c([H])c3[H] |
| TCMBANKIN048234 | Anhydroalkannin | 2-[(6Z)-2,9-dimethyldeca-2,6,8-trien-5-yl]-5,8-dihydroxynaphthalene-1,4-dione; AC1NSXHP | 270.28 g/mol | ||
| TCMBANKIN048585 | Pseudolaric acid A | 82508-32-5; 2,4-Pentadienoic acid, 5-(4a-(acetyloxy)-3,4,4a,5,6,9-hexahydro-3,7-dimethyl-1-oxo-1H-4,9a-ethanocyclohepta(c)pyran-3-yl)-2-methyl-, (3alpha(2E,4E),4alpha,4aalpha,9aalpha)-(-)-; pseudolaricacid a; NSC 615487; 2,4-Pentadienoic acid, 5-(4a-(acetyloxyl)-3,4,4a,5,6,9-hexahydro-3,7-dimethyl-1-oxo-1H-4,9a-ethanocyclohepta(c)pyran-3-yl)-2-methyl-, (3-alpha(2E,4E),4-alpha,9a-alpha)-(-)- (9CI) | 388.45 | ||
| TCMBANKIN048627 | shikonofuran e | [1-[5-3-furanyl]-4-methyl-3-penten-1-yl]3-methyl-2-butenoate; Shikonofuran E; [1-[5-(2,5-dihydroxyphenyl)furan-3-yl]-4-methylpent-3-enyl] 3-methylbut-2-enoate; AC1NT0DX; BDBM50363753; 85022-62-4; CHEMBL1944654 | C21H24O5 | 356.4 g/mol | CC(=CCC(C1=COC(=C1)C2=C(C=CC(=C2)O)O)OC(=O)C=C(C)C)C |
| TCMBANKIN048642 | methyl pseudolarate b | C24H30O8 | 446.5 g/mol | CC(=CC=CC1(C2CCC3(C2(CCC(=CC3)C(=O)OC)OC(=O)C)C(=O)O1)C)C(=O)OC | |
| TCMBANKIN049341 | shikonofuran B | [1-[5-3-furanyl]-4-methyl-3-penten-1-yl]2-methylbutanoate; AC1NT0DO; 85022-65-7; shikonofuran b; [1-[5-(2,5-dihydroxyphenyl)furan-3-yl]-4-methylpent-3-enyl] 2-methylbutanoate; Shikonofuran B | C21H26O5 | 358.43 | CCC(C)C(=O)OC(CC=C(C)C)C1=COC(=C1)C2=C(C=CC(=C2)O)O |
| TCMBANKIN050208 | shikonofuran d | 85022-63-5; CHEMBL1946216; Shikonofuran D; [1-[5-(2,5-dihydroxyphenyl)furan-3-yl]-4-methylpent-3-enyl] 2-methylpropanoate; BDBM50363754; AC1NT0DU | C20H24O5 | 344.4 g/mol | CC(C)C(=O)OC(CC=C(C)C)C1=COC(=C1)C2=C(C=CC(=C2)O)O |
| TCMBANKIN058114 | trans-caffeic acid | 3-(3,4-dihydroxy-phenyl)-acrylic acid; caffeic acid; Caffeate; Lopac-C-0625; 71693-97-5; DivK1c_006624; KBio2_007302; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NCGC00015206-02; CAS-3331-39-5; 60020_FLUKA; AI3-63211; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid polymer; (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NSC623438; 4-(2'-Carboxyvinyl)-1,2-dihydroxybenzene; KBio2_004734; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; CHEMBL1320034; AIDS-002287; AIDS002287; 501-16-6; CHEBI:36281; Prestwick1_000902; KBio1_001568; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; AKOS000273846; OR1165; SMR000058214; Spectrum2_001612; 3,4-dihydroxycinnamate; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeicacid; KOP; AC1NO658; CCRIS 847; Caffeic acid dehydrogenation homopolymer; SPECTRUM1503987; Spectrum4_001694; SCHEMBL3682144; NCGC00017364-01; NCGC00022654-08; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene; 78734C5A-1281-44D4-B8A0-A3188AD437E3; cis-Caffeic acid; 3-(3,4-dihydroxyphenyl)acrylic acid; Cinnamic acid, 3,4-dihydroxy-; KBioGR_001988; 3,4-Dihydroxybenzeneacrylic acid; 3,4-dihydroxycinnamic acid; trans-caffeic acid; AIDS-026339; NCGC00015206-01; HSDB 7088; ZINC4482687; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; 3-(3,4-dihydroxyphenyl)prop-2-enoate; Isocaffeic acid; SBB006475; InChI=1/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2; NCGC00017364-02; EU-0100208; C01197; MolPort-001-759-162; KBioSS_002166; Caffeic acid pure; caffeic acid ; trans-Caffeate; (2E)-3-(3,4-dihydroxyphenyl)acrylic acid; NSC 57197; (2E)-3-(3,4-Dihydroxyphenyl)-2-propenoic acid; Spectrum_001686; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, (E)-; KBio2_002166; Caffeic acid, cis-; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; 3,4-Dihydroxybenzeneacrylate; 3-(3,4-Dihydroxy phenyl)-2-propenoic acid; 4361-87-9; 3,4-Dihydroxy-trans-cinnamate; caffeicacid; AR-360/40806927; EINECS 206-361-2; 60018_FLUKA; Caffeic acid polymer; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; NCGC00022654-04; ZX-AL002121; C0625_SIGMA; SDCCGMLS-0002982.P003; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid, homopolymer; SPBio_001643; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)- (9CI); NCGC00017364-03; 3-(3,4-dihydroxyphenyl)prop-2-enoic acid; AC1LU7RL; SPBio_002943; CHEBI:16433; AIDS026339; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, homopolymer; CHEBI:17395; TNP00311; SpecPlus_000528; Prestwick0_000902; MLS000069738; 3,4-dihydroxy-cinnamic acid; 3-(3,4-Dihydroxyphenyl)propenoic acid; NCI60_004400; NSC57197; Caffeic; Lopac-C-0625; NCGC00015206-01; Caffeic acid; cis-Caffeic acid; NCGC00017364-01; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; C01481; 331-39-5; NCGC00015206-02; CAS-3331-39-5; 3,4-Dihydroxycinnamic acid; CHEBI:17395; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; TNP00311; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeate; 1- coffee acid | C9H8O4 | 180.16 g/mol | C1=CC(=C(C=C1C=CC(=O)O)O)O |
| TCMBANKIN058155 | dipotassiumrabdosiin | np02140176-40;(2R)-3-(3,4-dihydroxyphenyl)-2-[(1R,2S)-1-(3,4-dihydroxyphenyl)-3-[(2R)-3-(3,4-dihydroxyphenyl)-1-oxido-1-oxopropan-2-yl]oxycarbonyl-6,7-dihydroxy-1,2-dihydronaphthalene-2-carbonyl]oxypropanoate; AC1NSZ89 | C36H28O16-2 | C1=CC(=C(C=C1CC(C(=O)[O-])OC(=O)C2C(C3=CC(=C(C=C3C=C2C(=O)OC(CC4=CC(=C(C=C4)O)O)C(=O)[O-])O)O)C5=CC(=C(C=C5)O)O)O)O | |
| TCMBANKIN058752 | shikonin | HMS1990P11; 517-89-5; ST2402660; SBB066976; BSPBio_001270; AJ-32590; NEZONWMXZKDMKF-SNVBAGLBSA-N; N1643; (+)-Shikonin; HY-N0822; DTXSID30199653; NCGC00163489-01; 517S895; MLS006010149; CS-5906; 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methylpent-3-enyl]naphthalene-1,4-dione; HMS1792P11; AB0013814; RL03907; SR-05000001466-3; (R)-(+)-Shikonin; 1,4-NAPHTHOQUINONE, 5,8-DIHYDROXY-2-(1-HYDROXY-4-METHYL-3-PENTENYL)-, (+)-; BP-30212; J-502235; NSC 252844; SR-05000001466-1; s8279; HSDB 8100; CCG-208272; C17412; SCHEMBL33969; FT-0651798; CCRIS 6492; 874325-10-7; 3IK6592UBW; AC-26871; 5,8-Dihydroxy-2-[(1R)-1-hydroxy-4-methyl-pent-3-enyl]naphthalene-1,4-dione; HMS3403P11; BRN 2058010; KB-210224; AK105374; CHEBI:81068; CTK4J4851; NCGC00163489-02; NCGC00163489-04; N2643; KS-00001FJP; AC1LA0SH; 1,4-Naphthalenedione, 5,8-dihydroxy-2-(1-hydroxy-4-methyl-3-pentenyl)-, (R)-; 5,8-dihydroxy-2-[(1r)-1-hydroxy-4-methylpent-3-en-1-yl]-1,4-naphthoquinone; TR-031448; Shikonin S; AC1Q6B9B; 1,4-Naphthalenedione, 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-3-pentenyl]-; ANW-73225; Tokyo Violet; MolPort-005-932-876; Shikonine; UNII-3IK6592UBW; W-2767; 876010-87-6; CJ-31254; (+)-5,8-Dihydroxy-2-(1-hydroxy-4-methyl-3-pentenyl)-1,4-naphthoquinone; 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methylpent-3-en-1-yl]-1,4-dihydronaphthalene-1,4-dione; SR-05000001466; 1,4-Naphthalenedione,5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-3-penten-1-yl]-; (R)-5,8-Dihydroxy-2-(1-hydroxy-4-methylpent-3-en-1-yl)naphthalene-1,4-dione; MFCD00075680; SMR002530673; AKOS015900416; AS-13554; ZINC2015152; (-)-Shikonin; BG01580835; I664; Isoarnebin 4; HMS2089L09; 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methylpent-3-enyl]naphthalene-1,4-dione; 5,8-Dihydroxy-2-((R)-1-hydroxy-4-methyl-pent-3-enyl)-[1,4]naphthoquinone; 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-pent-3-enyl]naphthalene-1,4-dione; BSPBio_001270; AIDS094462; AIDS-094462; 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-pent-3-enyl]-1,4-naphthoquinone; 1,4-Naphthalenedione, 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-3-pentenyl]-; NCGC00163489-01; Isoarnebin 4 | C16H16O5 | 288.3 | CC(=CCC(C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C |
| TCMBANKIN058897 | deoxyshikonin | X908DXC99I; 1,4-Naphthalenedione,5,8-dihydroxy-2-(4-methyl-3-penten-1-yl)-; D2117; 43043-74-9; DTXSID80195660; C18133; CJ-29399; 11-Deoxyalkannin; 5,8-Dihydroxy-2-(4-methyl-3-pentenyl)-1,4-naphthalenedione; 5,8-dihydroxy-2-(4-methylpent-3-enyl)naphthalene-1,4-dione; 1,4-Naphthalenedione, 5,8-dihydroxy-2-(4-methyl-3-pentenyl)-; CHEBI:81530; BG00979346; ARNEBIN-7; NSC 179184; Arnebin 7; AC1L40II; CHEMBL486627; SR-05000013699-1; NSC179184; 9368AF; MolPort-035-785-199; 5,8-Dihydroxy-2-(4-methyl-3-pentenyl)naphthoquinone; ZINC1730009; 5,8-Dihydroxy-2-(4-methyl-3-pentenyl)naphthoquinone #; UNII-X908DXC99I; MFCD00144053; C-56477; VOMDIEGPEURZJO-UHFFFAOYSA-N; Deoxyshikonin; FT-0749847; SR-05000013699; CCG-208460; NSC-179184; AC1Q6B9I; SCHEMBL2873443;Arnebin 7;NSC 179184; 5,8-dihydroxy-2-(4-methylpent-3-enyl)naphthalene-1,4-dione; Deoxyshikonin; 43043-74-9; NSC179184; 5,8-Dihydroxy-2-(4-methyl-3-pentenyl)naphthoquinone; ARNEBIN-7; 1,4-Naphthalenedione, 5,8-dihydroxy-2-(4-methyl-3-pentenyl)-; 5,8-dihydroxy-2-(4-methylpent-3-enyl)-1,4-naphthoquinone | C16H16O4 | 272.29 g/mol | CC(=CCCC1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)C |
| TCMBANKIN059397 | 7-angeloylheliotridine | rivularine; o7-angeloylretronecine | C13H19NO3 | 237.29 g/mol | CC=C(C)C(=O)OC1CCN2C1C(=CC2)CO |
| TCMBANKIN060635 | propionylshikonin | C19H20O6 | 344.4 g/mol | CCC(=O)OC(CC=C(C)C)C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O | |
| TCMBANKIN060693 | Sitogluside | C35H60O6 | 576.85g/mol | CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC5C(C(C(C(O5)CO)O)O)O)C)C)C(C)C | |
| TCMBANKIN060966 | gondoic acid | C20H38O2 | 310.5 g/mol | CCCCCCCCC=CCCCCCCCCCC(=O)O | |
| TCMBANKIN061161 | eicosanol;n-eicosanol | C20H42O | 298.55 | CCCCCCCCCCCCCCCCCCCCO | |
| TCMBANKIN061166 | octadecyl caffeate;octadecyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate;octadecanyl caffeate | C27H44O4 | 432.6 g/mol | CCCCCCCCCCCCCCCCCCOC(=O)C=CC1=CC(=C(C=C1)O)O | |
| TCMBANKIN061403 | Abiol | AIDS209944; Methyl Parasept; H3647_SIGMA; Methyl p-hydroxybenzoate; BRN 0509801; FEMA Number 2710; p-Methoxycarbonylphenol; 4-HYDROXY-BENZOIC ACID METHYL ESTER; Benzoic acid, p-hydroxy-, methyl ester; Nipagin M; 4-Hydroxybenzoic acid, methyl ester; Nipagin; p-Oxybenzoesauremethylester [German]; D01400; Methyl chemosept; p-Hydroxybenzoic methyl ester; 4-(Methoxycarbonyl)phenol; Tegosept M; 4-10-00-00360 (Beilstein Handbook Reference); Aseptoform; H6654_SIAL; Methyl 4-hydroxybenzoate; Maseptol; BENZOIC ACID,4-HYDROXY,METHYL ESTER; AI3-01336; NCGC00159376-02; Methylparaben (TN); Metaben; Methyl-p-hydroxybenzoate; 99-76-3; Preserval M; Methylparaben (NF); Methyl parahydroxybenzoate (JP15); ST5214511; p-Hydroxybenzoic acid methyl ester; CCRIS 3946; Methyl ester of p-hydroxybenzoic acid; Methylparaben; p-Hydroxybenzoic acid, methyl ester; Caswell No. 573PP; FEMA No. 2710; NCGC00159376-03; p-Carbomethoxyphenol; Methylben; 47889_SUPELCO; NSC3827; ZINC00001712; AIDS-209944; Preserval; HSDB 1184; Metoxyde; Methaben; Moldex; WLN: QR DVO1; 4-Hydroxybenzoic acid methyl ester; InChI=1/C8H8O3/c1-11-8(10)6-2-4-7(9)5-3-6/h2-5,9H,1H; Solbrol M; Methylparaben [USAN]; 54752_FLUKA; Benzoic acid, 4-hydroxy-, methyl ester; Methyl parahydroxybenzoate; component of Heb-Cort MC; 54750_FLUKA; NSC406127; Methyl Butex; Solbrol; Methyl paraben; Paridol; EINECS 202-785-7; M8911_SIAL; Methyl p-oxybenzoate; NSC 3827; W271004_ALDRICH; EPA Pesticide Chemical Code 061201; Methyl parahydroxybenzoate (TN); Methylester kyseliny p-hydroxybenzoove [Czech]; Septos; methyl p-hydroxybenzoate; 4-hydroxybenzoic acid methyl ester; methyl-4-hydroxybenzoate; Methyl paraben; methylparaben | C8H8O3 | 152.15 g/mol | COC(=O)C1=CC=C(C=C1)O |
| TCMBANKIN061473 | Isovanillin | 3-Hydroxy-4-anisaldehyde; 3-Hydroxy-4-methoxybenzaldehyde; FT-0615821; ANW-34085; 4-Methoxy-3-hydroxy-benzaldehyde; DSSTox_RID_83498; ACMC-209n07; 4-methoxy-5-hydroxybenzaldehyde; NCGC00247609-01; BR-26987; SMR000156287; 143685_ALDRICH; BG01499429; CHEMBL275563; AK-26987; SBB008245; SC-05820; Q-100718; 3-Hydroxy-4-methoxybenzaldehyde; 3-hydroxy-4-anisaldehyde; MCULE-7646011311; 621-59-0; PubChem7770; F1995-0251; RTC-060637; 3-hydroxy-4-methoxy- benzaldehyde; 3-hydroxy-4-methoxy- benzaldehyde;BB_NC-2245; 3-Hydroxyanisaldehyde; AJ-16240; DSSTox_GSID_49423; 4A9N90H9X6; PS-4589; Isovanilline; 3-Hydroxy-para-anisaldehyde; MolPort-000-146-016; 3-hydroxy-4methoxy-benzaldehyde; NSC82996; SCHEMBL70256; BC204204; JVTZFYYHCGSXJV-UHFFFAOYSA-N; Tox21_202858; 4-Methoxy-3-hydroxybenzaldehyde; KS-000002MN; DTXSID7049423; 3-hydroxy-4-methoxy benzaldehyde; p-Anisaldehyde, 3-hydroxy- (8CI); Benzaldehyde, 3-hydroxy-4-methoxy-; AN-15747; D0E9CD; EBD684885; isovanillin; I0519; LS10550; A833619; 59927_FLUKA; HMS3348H19; Isovanicaline; 4-methoxy-3-oxidanyl-benzaldehyde; 3-Hydroxy-4-methoxy-benzaldehyde; LS-25072; 4-08-00-01764 (Beilstein Handbook Reference); HMS2194I16; AC-541; KSC354M3B; ZINC164617; Isovanillin, >=95.0%; ISOVANILLIN; ST50213460; I01-0153; BBL023550; NCGC00260404-01; BG00600677; NSC 82996; WLN: VHR CQ DO1; isovanilin; BRN 1073021; NSC-82996; 3-hydroxy-4-methoxy-benzaldehyde; CJ-02189; ZB008229; MLS000574853; Oxy-3 methoxy-4 benzaldehyde; DSSTox_CID_29383; CS-W009023; NCIOpen2_001085; 3-Hydroxy-4-methoxybenzaldehyde, 99%; DB-010058; 3-Hydroxyanisaldehyde; Isovanillin; 59940_FLUKA; ST24022906; AC1Q469E; STK400134; TRA0093875; InChI=1/C8H8O3/c1-11-8-3-2-6(5-9)4-7(8)10/h2-5,10H,1H; AKOS000120260; 3-hydroxy4-methoxybenzaldehyde; M-6105; CAS-621-59-0; TC-060637; TL8004050; AB1002458; CM13992; Oxy-3 methoxy-4 benzaldehyde [French]; p-Anisaldehyde, 3-hydroxy-; CTK2F4630; iso-Vanillin; AC1L1YWO; 5-Formylguaiacol; FT-0615853; 21I590; isovaniline; ZINC00164617; RP21587; KB-32136; BDBM50240367; 3-Hydroxy-p-anisaldehyde; P-Anisaldehyde, 3-hydroxy-(8CI); UNII-4A9N90H9X6; EINECS 210-694-9; MFCD00003369 | C8H8O3 | 152.15 | COC1=C(C=C(C=C1)C=O)O |
| TCMBANKIN061496 | calycosin | HSDB 8109; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)chromen-4-one; CHEBI:17793; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 09N3E8P7TA; calycosin (OLD); 20575-57-9; HY-N0519; ZINC6018563; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-1-benzopyran-4-one; 3'-hydroxy-formononetin; calycosin ; LMPK12050056; MEGxp0_001325; BRD-K05039497-001-01-6; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',7-dihydroxy-4'-methoxy-isoflavone; AKOS015896719; UNII-09N3E8P7TA; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-; 3', 7-dihydroxy-4'-methoxyisoflavone; 575C579; C01562; HMS2268B05; C-17889; MolPort-001-741-659; Calycosin; X1103; SCHEMBL73013; Q-100254; AC1NQX1G; 7-hydroxy-3-(3-hydroxy-4-methoxy-phenyl)chromen-4-one; 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4-chromenone; 7-hydroxy-3-(3-hydroxy-4-methoxy-phenyl)chromone; CHEMBL241608; CS-3715; ZZAJQOPSWWVMBI-UHFFFAOYSA-N; BG01576591; MLS000876988; DTXSID70174580; 3',7-dihydroxy-4'-methoxyisoflavone; ACon1_000650; I07-0176; NP-004576; NCGC00169494-01; 3-(4-methoxy-3-oxidanyl-phenyl)-7-oxidanyl-chromen-4-one; MCULE-7559555984; 7,3'-dihydroxy-4'-methoxyisoflavone; A814711; N1412; 3'-hydroxyformononetin; FT-0630465; MFCD00210598; SMR000440659; AN-8397; AC-8043; 3',7-dihydroxy-4'-methoxy-isoflavone | C16H12O5 | 284.26 g/mol | COC1=C(C=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O)O |
| TCMBANKIN061561 | vanillic acid | CJ-02984; CHEBI:16632; Vanillate; CHEBI:30816; H36001_ALDRICH; InChI=1/C8H8O4/c1-12-7-4-5(8(10)11)2-3-6(7)9/h2-4,9H,1H3,(H,10,11; BRN 2208364; WKOLLVMJNQIZCI-UHFFFAOYSA-M; 94770_FLUKA; WLN: QVR DQ CO1; MLS000574833; Acide vanillique; vanillicacid; C06672; m-Anisic acid, 4-hydroxy-; VA (VAN); vanil-lic acid; 4-Hydroxy-3-methoxybenzoic acidion; 4-Hydroxy-3-methoxybenzoic acid; Protocatechuic acid, 3-methyl ester; NSC3987; NSC 674322; DB02130; VANILLIC ACID; p-Vanillic acid; NSC 3987; ZB010900; 4-Hydroxy-3-methoxybenzoate; AIDS-018089; p-Hydroxy-m-methoxy-benzonic acid; 3-Methoxy-4-hydroxybenzoic acid; 4-hydroxy-3-methoxy-benzoic acid; NSC674322; 6746-48-1; 121-34-6; AC1L2LVA; Benzoic acid, 4-hydroxy-3-methoxy-; AI3-19542; SMR000156289; AIDS018089; SBB008280; W398802_ALDRICH; EINECS 204-466-8; 4-hydroxy-3-methoxy benzoic acid; 3-methoxy-4-hydroxybenzoic acid | C8H8O4 | 168.15 g/mol | COC1=C(C=CC(=C1)C(=O)O)O |
| TCMBANKIN061841 | Calycosin-7-0-β-D-glucopyranoside | 4H-1-Benzopyran-4-one, 7-(beta-D-glucopyranosyloxy)-3-(4-methoxyphenyl)-; MEGxp0_000395; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; LMPK12050014; 486-62-4; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-chromone; Formononetin glucoside; STOCK1N-14986; 75375_FLUKA; 3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranoside; ACon1_000463; ZINC01081322; 3-(4-methoxyphenyl)-7-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]-4-chromenone; CHEBI:7775; 3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-chromen-4-one; Ononin; C10509; Formononetin 7-O-glucoside; Formononetin-7-O-beta-D-glucopyranoside; Formononetin-7-glucoside; ononin | C22H22O9 | 430.4 | COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)OC4C(C(C(C(O4)CO)O)O)O |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab